Skip to main content

Table 2 Health challenges among MS, epilepsy, and headache patients during COVID-19

From: Knowledge, attitudes, and impact of COVID-19 pandemic among neurology patients in Jordan: a cross-sectional study

  Multiple sclerosis (n = 80)
n (%)
Epilepsy (n = 150)
n (%)
Headache (n = 40)
n (%)
Variables Total Patients with new relapses (%) Total Patients with increased seizure (%) Total Patients with increased headache (%)
Discontinuation of medication (or regular infusions)
 Yes 13 (17.57) 5 (38.46) 30 (20.13) 23 (76.67) 10 (25.00) 7 (70.00)
 No 61 (82.43) 26 (42.62) 119 (79.87) 56 (47.06) 30 (75.00) 18 (60.00)
Reason of discontinuation
 Anxiety about the pandemic (and/or concerns regarding immune suppression side effects of DMT) 4 (30.77) 2 (50.00) 9 (34.62) 7 (77.78) 2 (20.00) 1 (50.00)
 Restricted accessibility due to the pandemic 3 (23.08) 1 (33.33) 12 (46.15) 9 (75.00) 2 (20.00) 1 (50.00)
 Others 6 (46.15) 2 (33.33) 5 (19.23) 3 (60.00) 6 (60.00) 5 (83.33)
Change in sleep pattern     
 Fewer hours at night and during the day    16 (10.74) 13 (81.25) 9 (22.50) 8 (88.89)
 Fewer hours at night and more during the day    13 (8.72) 6 (46.15) 3 (7.50) 1 (33.33)
 More hours of sleep    12 (8.05) 5 (41.67) 3 (7.50) 0 (0.00)
 No change    108 (72.48) 55 (50.93) 25 (62.50) 16 (64.00)
Reason of change in sleep pattern     
 Anxiety and fear of the pandemic    14 (34.15) 11 (78.57) 4 (28.57) 3 (75.00)
 Frequent lockdowns and work stoppage    15 (36.59) 5 (33.33) 3 (21.43) 0 (0.00)
 Othersa    12 (29.27) 8 (66.67) 7 (50.00) 5 (71.43)
  1. Variability in totals is due to missing values in some variables
  2. a“No specific reason” for epilepsy patients or “Headache itself” for headache patients